North America Metastatic Lung Adenocarcinoma Treatment Market Size & Outlook

The metastatic lung adenocarcinoma treatment market in North America is expected to reach a projected revenue of US$ 3,640.2 million by 2030. A compound annual growth rate of 11.1% is expected of North America metastatic lung adenocarcinoma treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,933.5
Forecast, 2030 (US$M)
$3,640.2
CAGR, 2025 - 2030
11.1%
Report Coverage
North America

North America metastatic lung adenocarcinoma treatment market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America metastatic lung adenocarcinoma treatment market, 2018-2030 (US$M)

Related Markets

North America metastatic lung adenocarcinoma treatment market highlights

  • The North America metastatic lung adenocarcinoma treatment market generated a revenue of USD 1,933.5 million in 2024.
  • The market is expected to grow at a CAGR of 11.1% from 2025 to 2030.
  • In terms of segment, chemotherapy was the largest revenue generating treatment in 2024.
  • Immunotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
  • Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.

North America data book summary

Market revenue in 2024USD 1,933.5 million
Market revenue in 2030USD 3,640.2 million
Growth rate11.1% (CAGR from 2025 to 2030)
Largest segmentChemotherapy
Fastest growing segmentImmunotherapy
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationChemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Other
Key market players worldwidePfizer Inc, Eli Lilly and Co, AstraZeneca PLC, Bristol-Myers Squibb Co, Boehringer Ingelheim, Novartis AG ADR, Merck KGaA, Roche Holding AG, GlaxoSmithKline, AbbVie Inc

Other key industry trends

  • In terms of revenue, North America region accounted for 39.5% of the global metastatic lung adenocarcinoma treatment market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 2,293.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Metastatic Lung adenocarcinoma Treatment Market Companies

Name Profile # Employees HQ Website

North America metastatic lung adenocarcinoma treatment market size, by country, 2018-2030 (US$M)

North America Metastatic Lung adenocarcinoma Treatment Market Outlook Share, 2024 & 2030 (US$M)

North America metastatic lung adenocarcinoma treatment market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more